S Kane1, L Dixon. 1. Department of Medicine, University of Chicago, Chicago, IL 60637, USA. skane@medicine.bsd.uchicago.edu
Abstract
BACKGROUND: Inflammatory bowel disease is associated with non-adherence to treatment with oral medications. AIM: To assess the intravenous infliximab adherence rate and identify risk factors for non-adherence to treatment. METHODS: Infliximab infusion dates for 1 June 2002-30 October 2003 were obtained. Additional information was obtained from two other administrative and patient-based databases. Non-adherence was defined as a 'No Show' designation for a scheduled appointment. Non-adherence rate, odds ratios for associations to 'No Show' appointments and analysis were performed to identify patient characteristics associated with non-adherent behaviour. RESULTS: One thousand hundred and eighty-five infliximab infusions were scheduled for 274 patients. Forty-eight (4%) of appointments were classified as 'No Show'. Six patients accounted for 13/48 (27%) of failed appointments; another 35 patients missed one appointment. 'No Show' appointments were more likely to be for female patients, those on concomitant immunomodulators and those >18 weeks from initial infusion. Patients who missed >1 appointment were more likely to be female and have Medicaid vs. those with only one missed appointment (P < 0.05). Indication, patient area code and race were not significantly associated with single or repeated No Show behaviour. CONCLUSIONS: Overall, the non-adherence rate for infliximab is low. Risk factors that may contribute to non-adherence to treatment include female gender and maintenance dosing.
BACKGROUND:Inflammatory bowel disease is associated with non-adherence to treatment with oral medications. AIM: To assess the intravenous infliximab adherence rate and identify risk factors for non-adherence to treatment. METHODS:Infliximab infusion dates for 1 June 2002-30 October 2003 were obtained. Additional information was obtained from two other administrative and patient-based databases. Non-adherence was defined as a 'No Show' designation for a scheduled appointment. Non-adherence rate, odds ratios for associations to 'No Show' appointments and analysis were performed to identify patient characteristics associated with non-adherent behaviour. RESULTS: One thousand hundred and eighty-five infliximab infusions were scheduled for 274 patients. Forty-eight (4%) of appointments were classified as 'No Show'. Six patients accounted for 13/48 (27%) of failed appointments; another 35 patients missed one appointment. 'No Show' appointments were more likely to be for female patients, those on concomitant immunomodulators and those >18 weeks from initial infusion. Patients who missed >1 appointment were more likely to be female and have Medicaid vs. those with only one missed appointment (P < 0.05). Indication, patient area code and race were not significantly associated with single or repeated No Show behaviour. CONCLUSIONS: Overall, the non-adherence rate for infliximab is low. Risk factors that may contribute to non-adherence to treatment include female gender and maintenance dosing.
Authors: Jennifer L Bennett; Christina Y Ha; Jonathan E Efron; Susan L Gearhart; Mark G Lazarev; Elizabeth C Wick Journal: World J Gastroenterol Date: 2015-01-28 Impact factor: 5.742
Authors: Christopher Ma; Chad J Evaschesen; Grenvil Gracias; Vivian W Huang; Darryl K Fedorak; Karen I Kroeker; Levinus A Dieleman; Brendan P Halloran; Richard N Fedorak Journal: Can J Gastroenterol Hepatol Date: 2015-06-12
Authors: Herma H Fidder; Maartje M J Singendonk; Mike van der Have; Bas Oldenburg; Martijn G H van Oijen Journal: World J Gastroenterol Date: 2013-07-21 Impact factor: 5.742
Authors: Ali Keshavarzian; Lloyd Mayer; Bruce Salzberg; Michael Garone; Warren Finkelstein; Joseph Cappa; Myron Brand; Jon Hain; David Zelinger; Ronald Hegedus; Robert H Diamond; Ulka Campbell; Christi Lane; Paul Stang; John Watson; Fabio Cominelli Journal: Gastroenterol Hepatol (N Y) Date: 2007-05
Authors: Paul A Rufo; Lee A Denson; Francisco A Sylvester; Eva Szigethy; Pushpa Sathya; Ying Lu; Ghassan T Wahbeh; Laureen M Sena; William A Faubion Journal: J Pediatr Gastroenterol Nutr Date: 2012-07 Impact factor: 2.839